Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy

By Taneja Samir S   Smith Matthew R   Dalton James T   Raghow Sharan   Barnette Gary   Steiner Mitchell   Veverka Karen A  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 3, 2006-03 ,pp. : 293-305

Informa Healthcare

Access to resources Recommend Favorite

Bisphosphonates to Prevent Osteoporosis in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

By Smith M.R.  

Drugs & Aging, Vol. 20, Iss. 3, 2003-01 ,pp. : 175-183

Adis International

Access to resources Recommend Favorite

Management of the side effects of androgen deprivation therapy in men with prostate cancer

By Flaig Thomas W   Glodé L Michael  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2829-2841

Informa Healthcare

Access to resources Recommend Favorite

The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy

By  

Current Drug Targets, Vol. 14, Iss. 4, 2013-04 ,pp. : 420-440

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer

By McKay Rana R.   Gray Kathryn P.   Hayes Julia H.   Bubley Glenn J.   Rosenberg Jonathan E.   Hussain Arif   Kantoff Philip W.   Taplin Mary-Ellen  

Cancer, Vol. 121, Iss. 15, 2015-08 ,pp. : 2603-2611

Blackwell Publishing

Access to resources Recommend Favorite